APOE and Alzheimer disease: These results are limited by the small sample size; lack of randomization design to ω-3s vs. a placebo; intermittent compliance with ω-3 supplementation due to travel by patients 2, 4, and 12; diagnostic heterogeneity at baseline: 3 patients with SCI in the ApoE ε3/ε3 group vs. 2 with SCI and 1 with MCI-AD in the ApoE ε3/ε4 group; and the definition of the green zone M1/M2 ratio as 1–4 based on the observed relation of optimal M1-M2 to optimal MFI.